US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

27.74

+0.31001.13%

Post-market: 27.740.00000.00%16:10 EDT

Volume:188.43K

Turnover:5.22M

Market Cap:1.15B

PE:- -

High:27.81

Open:27.47

Low:27.47

Close:27.43

52wk High:30.21

52wk Low:25.69

Shares:41.60M

Float Shares:41.60M

Volume Ratio:0.79

T/O Rate:0.45%

Dividend:1.51

Dividend Rate:5.44%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Average Returns Exceed 20%! Over 90% of Private Fund Products Post Positive Returns This Year

Interest Rate Cuts Fuel Diesel Rally as Autumn Surge Outlook Strengthens

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Press Release: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Can A Crypto Quant Firm Scale Like A Hedge Fund? Algoz Thinks, So Here's The Data

Immunocore reports second quarter financial results and provides a business update

ProQR Announces Second Quarter 2025 Operating and Financial Results

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Smart Money Reduces US Stock Long Positions as Retail Investors Turn Greedy

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Press Release: Gentex Announces Closing of VOXX International Acquisition

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":27.74,"timestamp":1757966400000,"preClose":27.43,"halted":0,"volume":188432,"hourTrading":{"tag":"盘后","latestPrice":27.74,"preClose":27.74,"latestTime":"16:10 EDT","volume":12,"amount":332.88,"timestamp":1757967003919},"delay":0,"floatShares":41600001,"shares":41600001,"eps":0,"marketStatus":"Post-Mkt","change":0.31,"latestTime":"09-15 18:37:28 EDT","open":27.47,"high":27.805,"low":27.47,"amount":5224637.26539,"amplitude":0.012213,"askPrice":30.23,"askSize":100,"bidPrice":24.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1757980800000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":27.43,"sharesOutstanding":41600001,"nav":27.31,"aum":1135915818.89,"dividendRate":0.054434,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.5,"preClose":27.43,"latestTime":"08:23 EDT","volume":403,"amount":11484.550129,"timestamp":1757939029511},"postHourTrading":{"tag":"盘后","latestPrice":27.74,"preClose":27.74,"latestTime":"16:10 EDT","volume":12,"amount":332.88,"timestamp":1757967003919},"volumeRatio":0.792646,"impliedVol":0.2535,"impliedVolPercentile":0.8514},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":41600001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.792646,"shares":41600001,"dividePrice":1.51,"high":27.805,"amplitude":0.012213,"preClose":27.43,"low":27.47,"week52Low":25.69,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":27.74,"eps":0,"divideRate":0.054434,"volume":188432,"delay":0,"ttmEps":0,"open":27.47,"prevYearClose":27.89,"prevWeekClose":27.43,"prevMonthClose":27.91,"prevQuarterClose":26.74,"fiveDayClose":27.33,"twentyDayClose":27.25,"sixtyDayClose":27.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"CTA","amount":0.1,"announcedDate":"2025-08-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-26","defaultRemindTime":1756215000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-26","currency":"USD","dateTimestamp":1756180800000,"payDate":"2025-08-29"},{"date":"2025-06-25","symbol":"CTA","amount":0.25,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1122976738","title":"Average Returns Exceed 20%! Over 90% of Private Fund Products Post Positive Returns This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1122976738","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122976738?lang=en_us&edition=fundamental","pubTime":"2025-09-14 08:11","pubTimestamp":1757808669,"startTime":"0","endTime":"0","summary":"2025 has proven to be a favorable year for private fund institutions. Latest data reveals that private securities products have achieved solid returns across the board, with many star equity private...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","159982","399300"],"gpt_icon":0},{"id":"1150921586","title":"Interest Rate Cuts Fuel Diesel Rally as Autumn Surge Outlook Strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=1150921586","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150921586?lang=en_us&edition=fundamental","pubTime":"2025-09-03 07:54","pubTimestamp":1756857268,"startTime":"0","endTime":"0","summary":"Analysts indicate that if the Federal Reserve cuts interest rates this month, it will boost industrial activity powered by diesel - the \"workhorse fuel\" - potentially extending the summer rally in...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2559696494","title":"Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559696494","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559696494?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201660,"startTime":"0","endTime":"0","summary":"Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functional","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133827/0/en/Century-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CNBKA","IPSC","CTA","LENZ","BK4007","BK4505","BK4139"],"gpt_icon":0},{"id":"2559062469","title":"Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2559062469","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559062469?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029100,"startTime":"0","endTime":"0","summary":"Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita procedure sustained weight loss after GLP-1 discontinuation; incr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132116/0/en/Fractyl-Health-Announces-Second-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS","CTA"],"gpt_icon":0},{"id":"2558498626","title":"Press Release: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2558498626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558498626?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:00","pubTimestamp":1754996400,"startTime":"0","endTime":"0","summary":"Trial of Budoprutug in Primary Membranous Nephropathy  Expected to Initiate in the Coming Weeks. Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability and Favorable Tolerability in Non-clinical Studies;Phase 1 Trial Expected to Initiate in the Coming Weeks, with Initial Data Anticipated in First Half 2026. CLYM116 Focused Webcast Event, Including New Preclinical Data, Planned for September 2025;IND or CTA Submission for IgA Nephropathy  Expected in Second Half 2025. Strong Financial Position, with Cash Runway Expected Through 2027. WELLESLEY HILLS, Mass., Aug. 12, 2025  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025 and provided business updates.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BMS","BK4139","CTA","SLE","BK4077","BK4539","BK4199","ITP"],"gpt_icon":0},{"id":"2558765015","title":"Can A Crypto Quant Firm Scale Like A Hedge Fund? Algoz Thinks, So  Here's The Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2558765015","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558765015?lang=en_us&edition=fundamental","pubTime":"2025-08-08 22:59","pubTimestamp":1754665193,"startTime":"0","endTime":"0","summary":"Israeli asset manager Algoz reached $100M AUM in 2025, attributing its growth to algorithmic trading strategies and regulatory status. More to come.","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2025/08/08/Cryptocurrency-With-Blurred-City-Lights-.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2025/08/08/Cryptocurrency-With-Blurred-City-Lights-.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/25/08/47002088/can-a-crypto-quant-firm-scale-like-a-hedge-fund-algoz-thinks-so-heres-the-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["APT.USD.CC","TON.USD.CC","TON.USD.HKCC","APT.USD.HKCC","CTA"],"gpt_icon":0},{"id":"2557935563","title":"Immunocore reports second quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557935563","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557935563?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:00","pubTimestamp":1754564400,"startTime":"0","endTime":"0","summary":"KIMMTRAK (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Ph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129043/0/en/Immunocore-reports-second-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","BK4211","CM","CTA","BK4121","LU1878469433.USD","CRS","LU2211817866.USD","LU2413666426.HKD","BK4097","LU1721428933.USD","LU0963586101.USD","BK4139","BK4147","BK4567","IE0031619046.USD","LU2413666699.HKD","BK4195","BK4599","BK4533","BK4585","LU1093756168.USD","IE00B19Z4B17.USD","LU1093756325.SGD","OS","BK4007","IE00B66KJ199.SGD","PFS","IE00B7SZL793.SGD","BK4207","IE00BYQQ9H92.USD","ATOM","ORR","LU2065731478.USD","BK4588","PROC","BK4548","MTD","IE00BFXG0V08.USD","BK4006","ALT"],"gpt_icon":0},{"id":"2557563501","title":"ProQR Announces Second Quarter 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2557563501","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557563501?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:00","pubTimestamp":1754564400,"startTime":"0","endTime":"0","summary":"Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Anal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129058/33039/en/ProQR-Announces-Second-Quarter-2025-Operating-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU1721428933.USD","LU2041044095.USD","G","BK4139","RNA","BK4523","BK4585","LU0702159699.USD","LU2413666426.HKD","IE00BN0W2V16.EUR","LU2092937221.SGD","BK4567","LU2413666699.HKD","LU2229751404.USD","BK4106","BK4505","CTA","LU1165135440.EUR","A","EMA","BK4081","LU2089279066.USD","LU1543694498.USD","BK4121","BK4588","LU0347712357.USD","LU0702159343.USD","BK4226","LU1166156734.SGD","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"2556153048","title":"Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2556153048","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556153048?lang=en_us&edition=fundamental","pubTime":"2025-08-01 19:45","pubTimestamp":1754048700,"startTime":"0","endTime":"0","summary":"MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access PathwaySOLANA BEACH, Calif., Aug.  01, 2025  (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/01/3125723/0/en/Artelo-Biosciences-Receives-Favorable-UK-MHRA-Guidance-for-a-Phase-1-Trial-of-ART12-11-the-Company-s-Proprietary-CBD-TMP-Cocrystal-Being-Developed-for-the-Treatment-of-Anxiety-and-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4557","BK4211","BK4113","CTA","CBD","TMP","ACB","SSRI"],"gpt_icon":0},{"id":"1131537813","title":"Smart Money Reduces US Stock Long Positions as Retail Investors Turn Greedy","url":"https://stock-news.laohu8.com/highlight/detail?id=1131537813","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131537813?lang=en_us&edition=fundamental","pubTime":"2025-08-01 12:24","pubTimestamp":1754022281,"startTime":"0","endTime":"0","summary":"As retail investor greed reaches elevated levels, \"smart money\" is quietly retreating. Macro strategist Simon White recently published an analytical piece exploring a concerning phenomenon in current...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SVXY","UVXY","VIXmain","TVIX","CTA","VXMmain","VXX","VIXY"],"gpt_icon":0},{"id":"2555008794","title":"Pharming Group reports second quarter and first half 2025 financial results and provides business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008794","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555008794?lang=en_us&edition=fundamental","pubTime":"2025-07-31 13:00","pubTimestamp":1753938000,"startTime":"0","endTime":"0","summary":"Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST and Joenja revenue growthRUCONEST second quarter revenue increase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124636/0/en/Pharming-Group-reports-second-quarter-and-first-half-2025-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","ODD","BK4183","CTA","EEA","PHAR","BK4087","BK4543","BK4139","BK4585","IE0009354923.USD","BK4023","NICE","BK4588","BK4081","EMA","CHMP","BK4566","MAA","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2553042210","title":"Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2553042210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553042210?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:00","pubTimestamp":1753272000,"startTime":"0","endTime":"0","summary":"- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120186/0/en/Solid-Biosciences-Receives-FDA-Fast-Track-Designation-for-SGT-501-First-in-Class-Gene-Therapy-for-Catecholaminergic-Polymorphic-Ventricular-Tachycardia-CPVT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","CTA","FAST","IE00BYQQ9H92.USD","BK4130","BK4139","SLDB","IE00B5TLWC47.USD","BK4588","BK4535","IE00BFXG0V08.USD","FA","BK4585","BK4539","BK4104"],"gpt_icon":0},{"id":"2551931189","title":"Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551931189","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551931189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:30","pubTimestamp":1752496200,"startTime":"0","endTime":"0","summary":"July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3114750/0/en/Biodexa-Announces-Filing-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-Familial-Adenomatous-Polyposis-FAP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","CTA","BDRX","BK4139"],"gpt_icon":0},{"id":"2550637201","title":"Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2550637201","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550637201?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:35","pubTimestamp":1752064500,"startTime":"0","endTime":"0","summary":"Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112575/0/en/Moleculin-Expands-Phase-3-MIRACLE-Clinical-Trial-into-the-Country-of-Georgia-Enrollment-Update-and-Future-Plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","EMA","CTA","BK4081"],"gpt_icon":0},{"id":"2550557823","title":"Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550557823","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550557823?lang=en_us&edition=fundamental","pubTime":"2025-07-09 04:05","pubTimestamp":1752005100,"startTime":"0","endTime":"0","summary":"- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Desi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3112195/0/en/Solid-Biosciences-Announces-FDA-IND-and-Health-Canada-CTA-Approval-for-First-in-Class-Cardiac-Gene-Therapy-to-Treat-Catecholaminergic-Polymorphic-Ventricular-Tachycardia-CPVT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139","BK4130","CTA","FA","BK4539","BK4535"],"gpt_icon":0},{"id":"2536812996","title":"Press Release: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2536812996","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536812996?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:31","pubTimestamp":1747657860,"startTime":"0","endTime":"0","summary":"-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --. -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --. \"The first-in-human data for PM359 announced today represent a landmark moment for the industry and for our company, demonstrating the unequivocal power of Prime Editing to change patients' lives, with a single dose of PM359 providing potentially curative benefit in a matter of weeks,\" said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \"These data also reinforce the critical importance of ensuring Prime Medicine is positioned to withstand the challenges of the current environment, so that we can one day deliver the tremendou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4604","R","CFO","03160","BK4022","BK4232","CEO","BK4099","PRME","BK4555","TM","CTA","BK4585","BK4588"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4077","BK4539","SLE","CTA","BK4199","ITP","BK4139"],"gpt_icon":0},{"id":"2524111983","title":"Press Release: Gentex Announces Closing of VOXX International Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2524111983","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524111983?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"ZEELAND, Mich., April 01, 2025  -- Gentex Corporation  announced today that it has closed on the strategic acquisition of VOXX International, a global supplier of automotive and consumer electronics as well as premium audio equipment.Gentex is a technology company and long-time supplier of electro-optical products for the global automotive, aerospace, fire protection and medical industries. The company is best known for automotive electronics, but continues to grow its capabilities in vision systems, sensing, AI development, biometrics, home automation, and other smart technologies.Under the terms of the agreement, which was recently approved by VOXX shareholders, Gentex acquired all the issued and outstanding shares of VOXX common stock not already owned by Gentex for a purchase price of $7.50 per share. The Company expects its annual revenue to increase in the range of $325 million to $375 million as a result of the acquisition.\"We want to continue the legacy of VOXX Founder John Sha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4124","R","BK4232","CTA","GNTX","IE00BD6J9T35.USD","VOXX","BK4078"],"gpt_icon":0},{"id":"2523917675","title":"Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917675","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917675?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical mu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052163/36461/en/Voyager-Presents-Robust-Preclinical-Data-from-Tau-Targeting-Gene-Therapy-and-Antibody-Programs-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET","LU1169589451.USD","BK4192","PD","BK4023","CTA","LU1169590202.USD"],"gpt_icon":0},{"id":"2522539191","title":"Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539191?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"-- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders  ongoing, with dosing completed in two of four multiple ascending dose  cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025. -- Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025. Mr. Mandel-Brehm continued, \"We are also pleased to announce the selection of a development candidate, CMP-SYNGAP-01, for our SYNGAP1-related disorders program based on compelling data across our preclinical studies, including recent non-human primate studies. The discovery and selection of a novel regRNA-targeting antisense oligonucleotide  that increases SYNGAP1 protein levels underscores the transformative potential of our platform to identify and advance this novel class of therapeutic candidates for SYNGAP1-related disorders, a group of neurodevelopmental conditions with no approved therapies that we believe impacts app","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASO","CTA","TM","LU1169589451.USD","BK4555","BK4023","BK4139","BK4099","BK4200","CAMP","BK4604","BK4561","PD","LU1169590202.USD","BK4585","03160","BK4020","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}